Topics:
Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • University of Wisconsin • HR+ • NCI-CCC Breast Tumor Board Question • Breast Cancer, Non-metastatic • Her2-negative breast cancer
Would you offer adjuvant abemaciclib + an aromatase inhibitor to a patient with a local HR+HER- breast cancer reoccurrence while on tamoxifen that meets high-risk criteria?
High-risk criteria meaning >4 positive nodes and Ki67 >20%
Answer from: Medical Oncologist at Academic Institution
I would consider using abemaciclib and aromatase inhibitor therapy for a local recurrence while on adjuvant tamoxifen for someone who otherwise met the criteria for adjuvant therapy based on the FDA approval upon results of the monarchE trial (1). While not formally tested in this population, the on...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
In a patient with an ipsilateral, local reoccurrence of a HR+HER- breast cancer while on adjuvant tamoxifen, after appropriate staging to rule out distant metastases and definitive local therapy (mastectomy), I would offer adjuvant chemotherapy and an AI + abemaciclib. If she is not postmenopausal, ...
Comments
Medical Oncologist at Alvin & Lois Lapidus Cancer Institute Northwest Hospital
In this setting of recurrent disease, would you st...
In this setting of recurrent disease, would you st...
Answer from: Medical Oncologist at Community Practice
If I am understanding the question correctly, this is after the completion of curative-intent treatment for patients who had developed second cancer, while they were receiving the first adjuvant therapy using tamoxifen? -> If correct, my answer is YES.
As many of us now understand, the effective...